老马，我家6月确诊肺腺，6月份正版帕唑帕尼 ct基本无变化8 B; T" L2 e. H% F6 ?% q2 P
7月份易瑞沙 主灶基本无变化，胸膜转移灶增大4 k }! P% B+ m
8月份易瑞沙 主灶基本无变化，出现少量胸水 : D( e! \+ O! t/ S 9~10月中药 ct主灶大了近一倍，胸水增多，右下肺部分压缩不张 & u8 j. S. Y" i* ]9 U' Z9 v0 q' E 11月份阿西替尼 ct胸水增多，几乎到胸腔一半的位置了，! `, W m, b5 Q, w
其他与10月份ct无变化 * j6 ~+ A! [7 |* g7 V 现在吃了7天特， 咳嗽比较厉害- _4 d5 d2 I C% c$ L2 X
如不吃特，请问老马有什么建议？
Clinical response to a lapatinib-based therapy of a Li-Fraumeni Syndrome patient with a novel HER2-V659E mutation * k( O- K- ]3 s% n$ |. L9 c0 \Genomic characterization of recurrent breast and lung tumors developed over the course of 10 years in a 29-year-old patient with a germline p53 mutation (Li-Fraumeni Syndrome) identified oncogenic alterations in the HER2 and EGFR genes across all tumors, including HER2 amplifications, an EGFR-exon 20 insertion, and the first-in-human HER2-V659E mutation showing a phenotypic convergent evolution towards HER2 and EGFR alterations. Following the identification of HER2-activating events in the most recent lung carcinoma and in circulating tumor cells, we treated the reminiscent metastatic lesions with a lapatinib-based therapy. A clinical response both symptomatic and radiologic was achieved. HER2-V659E sensitivity to lapatinib was confirmed in the laboratory.
显身卡
0 X3 v$ X* F6 t2 f5 t2 |; [
